psychedelics investing Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
psychedelics investing Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
psychedelics investing Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
psychedelics investing Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
psychedelics investing A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
psychedelics investing Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
psychedelics investing Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
psychedelics investing Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
psychedelics investing Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
American Uranium's Lo Herma Resource Reaches 9.96Mlbs as Indicated Resources Grow 72% Prior to Publication of Planned Scoping Study
Angkor Resources' Subsidiary Meets with Cambodian National Refinery Systems to Discuss Potential In-Country Offtake for Block VIII Production
Noble Acquires North Bradshaw Property in Northern Ontario and Provides Final Information on Arrangement
Nuvau Minerals Strengthens Its Board and Technical Team with the Appointment of David Palmer as a Director and Michael Sutton as Technical Advisor to the Board
